Interleukin-2 Treatment in Older Patients with Kidney Cancer
Author Information
Author(s): S. Negrier, A. Mercatello, M. Bret, P. Thiesse, J.Y. Blay, B. Coronel, Y. Merrouche, R. Oskam, C.R. Franks, M. Clavel, J.F. Moskovtchenko, T. Philip
Primary Institution: Centre L. Berard
Hypothesis
Does continuous infusion of Interleukin-2 (IL2) affect response rates and toxicity in patients over 65 with metastatic renal cell carcinoma?
Conclusion
The study found that while IL2 therapy is feasible for older patients, it carries significant cardiac toxicity.
Supporting Evidence
- Three patients had objective responses, including one partial and two complete responses.
- 44% of patients experienced cardiac toxicity, which was a significant concern.
- All toxicities resolved within 1 to 2 weeks after treatment.
Takeaway
Doctors gave a special medicine called IL2 to older people with kidney cancer to see if it helps them get better, but it can also hurt their hearts.
Methodology
Patients received continuous infusion of IL2 for two 5-day periods with a 6-day break in between, and were monitored for responses and side effects.
Potential Biases
Potential bias due to the exclusion of patients with serious organ pathology.
Limitations
The study had a small sample size and excluded patients with significant health issues.
Participant Demographics
Participants were 25 patients over 65 years old, with a median age of 69, including 16 males and 9 females.
Want to read the original?
Access the complete publication on the publisher's website